Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Metastatic castration-resistant prostate cancer (CRPC) has a five-year survival rate of 28%. As histone deacetylases (HDACs) are overexpressed in CRPC, the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) was trialled in CRPC patients but found to be toxic and inefficacious. Previously, we show...

Descripción completa

Detalles Bibliográficos
Autores principales: Rana, Zohaib, Diermeier, Sarah, Walsh, Fearghal P., Hanif, Muhammad, Hartinger, Christian G., Rosengren, Rhonda J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540814/
https://www.ncbi.nlm.nih.gov/pubmed/34681244
http://dx.doi.org/10.3390/ph14101020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540814/
https://www.ncbi.nlm.nih.gov/pubmed/34681244
http://dx.doi.org/10.3390/ph14101020

Ejemplares similares